Breast Cancer
Conditions
Keywords
Breast Cancer
Brief summary
The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
Detailed description
A qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
Interventions
OTHERPhone interview
Collecting clinical and socio-demographic information.
Sponsors
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Are Hispanic, Latina, Black, or identify as socio-economically disadvantaged (any racial/ethnic background) as measured by an item of financial distress answering that they are having difficulty paying the bills no matter what they do to a question about their current household financial situation.18, 19 * report a history of Stage 1-3 breast cancer * reports HR+ breast cancer and confirm that they have had a discussion with their doctor about adjuvant ET; OR indicate that they are taking ET, even if they do not know their HR status, answer they are HR-, or do not recall having a discussion about ET) * not in active treatment (e.g., chemotherapy, radiation), with the exception of Herceptin * at least 3 months, but no more than 3 years out of completion of active treatment * no evidence of recurrent/metastatic disease * at least 18, but\< 45 years of age at diagnosis of first invasive breast cancer * English or Spanish speaking * are willing to consent to the interview
Exclusion criteria
* HR- breast cancer and indicate they are not taking ET * HR+ breast cancer but do not confirm discussion of ET or indicate they are taking ET * Stage 0 (DCIS) breast cancer * Recurrent or metastatic disease * Less than 3 months or more than 3 years post-active treatment * Less than 18 years old or ≥45 years old at diagnosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Decision-making around endocrine therapy in young women with HR+ breast cancer. | 3 months-3 years post active treatment | Open ended questions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Social support | 3 months-3 years post active treatment | Open ended questions |
| Health behaviors | 3 months-3 years post active treatment | Open ended questions |
| Barriers and challenges to endocrine therapy adherence | 3 months-3 years post active treatment | Open ended questions |
| Health literacy | 3 months-3 years post active treatment | Brief Health Literacy Screener (Chew items) |
| Menopausal symptoms | 3 months-3 years post active treatment | BCPT Symptom Checklist |
| Endocrine therapy adherence intervention preferences | 3 months-3 years post active treatment | Open ended questions |
Countries
United States
Outcome results
None listed